Ropivacaine

Structural formula
General
Non-proprietary name	Ropivacaine
other names	( S ) -1-propyl-2 ', 6'-dimethyl-2-piperidylcarboxyanilide; (-) - 1-Propyl-2 ', 6'-dimethyl-2-piperidylcarboxyanilide;
Molecular formula	C 17 H 26 N 2 O
External identifiers / databases
EC number	617-525-1
ECHA InfoCard	100.128.244
PubChem	175805
DrugBank	DB00296
Wikidata	Q279504
Drug information
ATC code	N01 BB09
Drug class	Local anesthetics
properties
Molar mass	274.41 g · mol -1
Melting point	144–146 ° C (ropivacaine) ; 260–262 ° C (ropivacaine hydrochloride) ; 269.5–270.6 ° C (ropivacaine hydrochloride monohydrate) ;
pK s value	8.1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Hydrochloride monohydrate; danger
H and P phrases	H: 318
	P: 280-305 + 351 + 338
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Ropivacaine (trade names: Naropin, Ropivacin ) is a local anesthetic of the amide type. It is derived from bupivacaine and has a relatively slow onset of action and a long duration of action (up to 12 hours). It was patented in 1985 by Apothekernes Laboratorium - Oslo, Norway - and has been marketed across Europe by AstraZeneca since its introduction in 1997 .

application

Ropivacaine is used in anesthesia for regional anesthesia and epidural anesthesia procedures such. B. used the epidural anesthesia .

effect

After Ropivaca administration, the motor blockade in the effective area should be less pronounced with the same pain elimination. This property makes it a widely used substance in obstetrics and for pain therapy after orthopedic operations, since it simplifies the painless mobilization of the patient. In addition, it should be less damaging to the heart and nerves than comparable other local anesthetics. With regard to the maximum dose, the product information from Naropin states that single doses of up to 250 mg ropivacaine (equivalent to approx. 33 ml ropivacaine 0.75%) were used and well tolerated for epidural anesthesia during surgical interventions. A limited number of patients received a single dose of 300 mg (corresponds to approx. 40 ml ropivacaine 0.75%) to block the brachial plexus , which was also well tolerated.

literature

S. Leone, S. Di Cianni, A., Casati, G. Fanelli: Pharmacology, toxicology, and clinical use of new long acting local anesthetics, ropivacaine and levobupivacaine. ( Memento of December 16, 2011 in the Internet Archive ) (PDF; 119 kB) In: Acta Biomed. 79 (2), 2008 Aug, pp. 92-105. PMID 18788503
Specialist information Naropin. As of June 4, 2013.

Individual evidence

↑ ^a ^b Cornelia Imming: ropivacaine. In: Römpp Chemistry Lexicon. Thieme Verlag, as of December 2006.
↑ ^a ^b The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals. 14th edition. 2006, ISBN 0-911910-00-X , p. 1426.
↑ ^a ^b Data sheet Ropivacaine hydrochloride monohydrate from Sigma-Aldrich , accessed on April 22, 2011 ( PDF ).
↑ Michael Heck, Michael Fresenius: Repetitorium Anaesthesiologie. Preparation for the anesthesiological specialist examination and the European diploma in anesthesiology. 3rd, completely revised edition. Springer, Berlin / Heidelberg / New York et al. 2001, ISBN 3-540-67331-8 , p. 804.

[Römpp-1] Cornelia Imming: ropivacaine. In: Römpp Chemistry Lexicon. Thieme Verlag, as of December 2006.

[MerckIndex-2] The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals. 14th edition. 2006, ISBN 0-911910-00-X , p. 1426.

[Sigma-3] Data sheet Ropivacaine hydrochloride monohydrate from Sigma-Aldrich , accessed on April 22, 2011 ( PDF ).

[4] Michael Heck, Michael Fresenius: Repetitorium Anaesthesiologie. Preparation for the anesthesiological specialist examination and the European diploma in anesthesiology. 3rd, completely revised edition. Springer, Berlin / Heidelberg / New York et al. 2001, ISBN 3-540-67331-8 , p. 804.